We are delighted to announce that the organization’s name has changed to European INstitUte of Molecular Medicine (EINUMM).
The new name reflects the aim and scope of our organization in line with the current research advancements on autoimmune and chronic diseases.
Autoimmune diseases are the leading cause of chronic diseases, and many patients struggle to fully control the symptoms of their disease, despite the availability of new and patient-friendly treatment options.
The difficulty in treating autoimmune diseases lies in their multifactorial nature, where the causing factors act synergistically to the onset and progression of autoimmune diseases. Therefore, in parallel with the appropriate medication, their effective treatment requires the management of the causing factors involved in the aggravation of this group of diseases.
Metabolomics provide data on the phenotype (the expression of genes under the influence of microbiome and environment) that shapes the treatment according to the patient’s characteristics regarding optimizing their medication and restoring metabolic disturbances, micronutrient deficiencies, microbiome imbalance, and inflammation management.
Overall, the European INstitUte of Molecular Medicine focuses on novel precision medicine approaches to better understand the molecular mechanisms that lead to the onset, prevention and effective treatment of autoimmune and chronic diseases.
Dr. Dimitris Tsoukalas, MD
President of European INstitUte of Molecular Medicine
